Medtechy’s Ten Most Popular Articles of 2018
2018 was an exciting year for Medtechy and we would like to thank you all for visiting, reading and sharing.
Over the course of 2018, we launched a number of new features to our site, including a new home page with up-to-date news and insight for the medical technology industry.
Additionally, we launched Medtechy Jobs, a recruiting platform for employees, companies and recruiters in the medical sales field. Our partnership with ZipRecruiter ensures that all paid job listings are distributed to millions of candidates throughout the United States.
The Medtechy company forums also received a significant upgrade with the addition of featured articles, top forums and the latest jobs listed on our sidebar, giving our visitors easier access to our best content.
The most popular articles from 2018 focused on Robotic Surgery, Medical Device Fraud and Sales tips for medical sales professionals. If you combine the pageviews from our healthcare forums, it’s clear that visitors have a sincere interest in learning about the next generation of surgical technology and preserving our healthcare system by holding individuals accountable for illegal and fraudulent activities.
In case you missed them the first time around, please enjoy our top 10 articles from 2018 and we look forward to continuing to provide interesting insight on medical technology and more in 2019.
Since last fall, MiMedx CEO, Parker Petit, and short-seller, Marc Cohodes, have been involved in a verbal battle over business practices and accounting at MiMedx. The accusations only intensified when an anonymous Mimedx employee sent a letter to Cohodes with detailed examples of misconduct by MiMedx and its executives.
September is going to be a big month for Mazor Robotics and Medtronic as they introduce their Mazor X Stealth Station at NASS in Los Angeles.
That's how the website for the new Netflix documentary, The Bleeding Edge, describes the medical device industry. For many of workers in the $400 billion medical device industry, hearing that first sentence will be hard to swallow, especially considering employees in the industry deeply care about the products they are developing, marketing and selling.
Writing about TransEnterix ($TRXC) has been fun in the past year as the company has consistently executed on the key priorities that CEO Todd Pope has laid out. As mentioned in our TransEnterix SWOT analysis after their most recent earnings call, the fourth quarter would be "the tell" when it comes to understanding overall business health and growth of TransEnterix.
During their most recent earnings call, TransEnterix shared some notable highlights in regards to their cash position, expanded indications and the sale of two Senhance systems thus far in Q1 of 2018. As outlined in their most recent earnings release, TransEnterix has made fair progress since the October FDA 510(k) clearance of the Senhance System.
TransEnterix just announced Q1 earnings with an additional update on Senhance system sales up to this point in Q2, which ends June 30th. On initial glance, you can tell the TransEnterix sales team has done a nice job shortening the typical sales cycle for capital equipment of this dollar amount
TransEnterix ($TRXC) released earnings Tuesday morning and the stock got crushed, trading down over 11% on the day. Is it an overreaction? Possibly. We're talking about a startup robotic surgery company, so wild trading days are to be expected. There will always be profit taking, as one year ago today, the stock was trading at .70. Even being down over 11% today, the stock is still at $4.70.
MiMedx not reporting Open Payment data has been written about at length. We asked the question in a post earlier this year and the Wall Street Journal had a fantastic piece asking the same questions a month later. With all of the attention being given to MiMedx and their business practices, one would think any physician receiving payments from them would self report those payments. The last thing a physician needs is a target on their back because of their work with a company under DOJ and FBI investigation.
Titan Medical has released a set of surgeon narrated video clips of successful single port general surgery procedures with their SPORT Surgical System in a preclinical setting. As you can see in their commercialization plan, Titan expects to continue the development and tooling while taking the necessary steps for FDA submission in 2018, with a projected regulatory clearance of SPORT in 2019.
The new year always comes with lofty goals, which typically start with unused gym memberships and unproductive quarterly planning meetings. On the contrary, writing out achievable goals help you from becoming overwhelmed and not giving up. They need to be hard, but not unrealistic.